Pages that link to "Q37287033"
Jump to navigation
Jump to search
The following pages link to Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy (Q37287033):
Displaying 38 items.
- Kallikreins as biomarkers for prostate cancer (Q26862434) (← links)
- Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer (Q33745069) (← links)
- Adjuvant medical therapy for prostate cancer (Q33758771) (← links)
- Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer (Q34086557) (← links)
- Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively (Q34332454) (← links)
- An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection (Q34677200) (← links)
- Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time (Q35188264) (← links)
- Prostate kallikrein markers in diagnosis, risk stratification and prognosis. (Q35683035) (← links)
- PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer (Q36033729) (← links)
- Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy (Q36142278) (← links)
- Tumor markers in prostate cancer I: blood-based markers (Q36607766) (← links)
- Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413 (Q36874598) (← links)
- Radiotherapy in the management of prostate cancer after radical prostatectomy (Q38104412) (← links)
- A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer (Q38192156) (← links)
- Active surveillance for clinically localized prostate cancer--a systematic review (Q38194533) (← links)
- PSA velocity: a systematic review of clinical applications (Q38224140) (← links)
- Imaging and evaluation of patients with high-risk prostate cancer. (Q38611187) (← links)
- Population-based study of grade progression in patients who harboured Gleason 3 3. (Q38788460) (← links)
- What's new in screening in 2015? (Q38871819) (← links)
- Prostate-specific Antigen Density Variation Rate as a Potential Guideline Parameter for Second Prostate Cancer Detection Biopsy (Q39564842) (← links)
- Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy. (Q41599456) (← links)
- Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient (Q41869922) (← links)
- Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer (Q42215015) (← links)
- Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy (Q42501562) (← links)
- PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy (Q43122510) (← links)
- Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer (Q44658335) (← links)
- Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population? (Q46304904) (← links)
- Careful Selection and Close Monitoring of Low-Risk Prostate Cancer Patients on Active Surveillance Minimizes the Need for Treatment (Q46770518) (← links)
- Recommandations de l’Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate (Q47123251) (← links)
- Novel approaches to improve prostate cancer diagnosis and management in early-stage disease (Q51176148) (← links)
- PCA3 as a diagnostic marker for prostate cancer: A validation study on a Swedish patient population (Q51747556) (← links)
- MR-based prognostic nomogram for prostate cancer after radical prostatectomy (Q51799851) (← links)
- Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy. (Q53373218) (← links)
- Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort (Q58799069) (← links)
- Recommandations en Onco-Urologie 2010 : Cancer de la prostate (Q63966222) (← links)
- Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance (Q85776030) (← links)
- Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review (Q94602192) (← links)
- [Prostate biopsy. Update for indication, procedure, and future developments] (Q95433559) (← links)